The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. | The U.S.
During the initial titration phase of up to 16 weeks, patients received increasing dosages of cinacalcet until the serum calcium concentration was <2.5 mmol/l, the highest possible dosage was ...
Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...
Cinacalcet is an effective treatment for secondary hyperparathyroidism in patientson dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...
Some results have been hidden because they may be inaccessible to you